Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
0.2% brimonidine/0.5% timolol fixed combination · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution |
| 2 | ACTIVE_COMPARATOR | Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution |
| 3 | ACTIVE_COMPARATOR | 0.2% brimonidine ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution | DRUG | 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening) |
| Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution | DRUG | Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening) |
| Brimonidine 0.2% ophthalmic solution | DRUG | Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening) |
Inclusion Criteria: * Diagnosis of ocular hypertension or glaucoma * Patient requires IOP-lowering therapy in both eyes Exclusion Criteria: * Uncontrolled medical conditions * Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |